Skip to main content
Premium Trial:

Request an Annual Quote

Molecular Devices' Q3 Revenue Misses Guidance; Firm Offers Limp Outlook

NEW YORK (GenomeWeb News) — Molecular Devices’ third-quarter revenues edged up 1 percent while its net income dipped almost 40 percent year over year, the company said this week.
Revenues for the quarter ended Sept. 30 rose to $45.5 million from $45.2 million in the same quarter last year. In July the company said it expected to post between $48 million and $52 million in revenue.
“While we were disappointed in our overall results this quarter, we continue to believe that we are well-positioned based on the quality of our existing product portfolio and the strength of our expected new product introductions over the next year,” Joseph Keegan, Molecular Devices’ president and CEO, said in a statement.
Keegan added that softer-than-expected demand from pharmaceutical companies during the quarter impacted the drug-discovery and life-sciences product lines, but that drug-discovery imaging exceeded the company’s expectations for the quarter.
Molecular Devices’ net income for the third quarter tumbled to $2.8 million from $4.6 million in the year-ago period. The company spent $5.7 million on R&D in the third quarter.
Molecular Devices said it expects to generate between $47 million and $52 million in fourth-quarter revenues, which is between a 1-percent decline and 9-percent increase over the same period last year. The firm said full-year revenue ought to come in between $180 million to $185 million, which would be flat year over year or a 2-percent increase.
As of Sept. 30, Molecular Devices had $13.3 million in cash and cash equivalents on hand.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more